With Matoke® Holdings’ first CE-marked medical device already in use in the NHS, Matoke® Pharma is currently developing RO™101 as an ideal medicinal product for the treatment of chronic non-healing wounds. We are collaborating with world-renowned scientists and surgeons at British universities and teaching hospitals to develop and bring to market ground-breaking new antimicrobial products for use across the world.

Matoke® Holdings Ltd has been granted UK patents covering various aspects of Reactive Oxygen® technology, with more patent applications currently being prosecuted in the UK and a number of other territories around the world. Reactive Oxygen® and the atom logo are trademarks of Matoke® Holdings Limited, registered in the UK and other territories.